Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H53N3O6 |
Molecular Weight | 551.7583 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
InChI
InChIKey=UXOWGYHJODZGMF-QORCZRPOSA-N
InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
Aliskiren – the only direct renin inhibitor which is clinically used as an antihypertensive drug. Aliskiren is the first of a new class of antihypertensive agents. Aliskiren is a new renin inhibitor of a novel structural class that has recently been shown to be efficacious in hypertensive patients after once-daily oral dosing. In short-term studies, it was effective in lowering blood pressure either alone or in combination with valsartan and hydrochlorothiazide, and had a low incidence of serious adverse effects. It was approved by the Food and Drug Administration in 2007 for the use as a monotherapy or in combination with other antihypertensives. Aliskiren is marketed under the trade name Tekturna. Aliskiren effectively reduces functional plasma renin activity by binding to renin with high affinity, preventing it from converting angiotensinogen to angiotensin I. The inhibition of renin by aliskiren is associated with a reduction in circulating levels of angiotensin I and II, with a resultant increase in plasma renin concentration and inhibit activation of mitogen-activated protein kinases ERK1 (p44) and ERK2 (p42).
Originator
Sources: http://adisinsight.springer.com/drugs/800010738 | https://www.ncbi.nlm.nih.gov/pubmed/21687346
Curator's Comment: # Novartis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL286 |
0.6 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TEKTURNA Approved UseAmturnide is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Amturnide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed combination drug is not indicated for initial therapy of hypertension. Amturnide is a combination of aliskiren, a renin inhibitor, amlodipine besylate, a dihydropyridine calcium channel blocker, and hydrochlorothiazide (HCTZ), a thiazide diuretic. Amturnide is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions: Not indicated for initial therapy. (1) Launch Date2007 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
273 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fasted |
|
252 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fasted |
|
108 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fed |
|
102 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fed |
|
290.2 ng/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALISKIREN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1580 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fasted |
|
1540 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fasted |
|
872 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fed |
|
1100 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fed |
|
1399 ng × h/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALISKIREN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41 h |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALISKIREN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg single, oral Highest studied dose |
healthy, 18 - 45 |
|
600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 53 |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (0.6%) Sources: |
300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Disorder fetal, Angioedema... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: Angioedema Angioedema Hypotension Impaired renal function Hyperkalemia |
150 mg 1 times / day steady, oral Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: |
unhealthy |
Other AEs: GI bleed, Knee hemarthrosis... Other AEs: GI bleed (serious, 1 patient) Sources: Knee hemarthrosis (serious, 1 patient) Diarrhea (below serious, 5 patients) Lower extremities weakness of (below serious, 1 patient) |
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Other AEs: Cellulitis, Pneumonia... Other AEs: Cellulitis (serious, 1 patient) Sources: Pneumonia (serious, 1 patient) Diabetic foot (serious, 1 patient) Choroidal neovascularisation (below serious, 1 patient) Foreign body sensation in eyes (below serious, 1 patient) Asteroid hyalosis (below serious, 1 patient) Retinal neovascularisation (below serious, 1 patient) Vision blurred (below serious, 1 patient) Vitreous detachment (below serious, 1 patient) Diarrhoea (below serious, 1 patient) Flatulence (below serious, 1 patient) Fatigue (below serious, 1 patient) Fungal skin infection (below serious, 1 patient) Respiratory tract infection (below serious, 1 patient) Sinusitis (below serious, 1 patient) Tooth fracture (below serious, 1 patient) Hypoglycaemia (below serious, 1 patient) Arthritis (below serious, 1 patient) Muscle spasms (below serious, 1 patient) Myalgia (below serious, 1 patient) Pain in extremity (below serious, 1 patient) Pain in jaw (below serious, 1 patient) Basal cell carcinoma (below serious, 2 patients) Paraesthesia (below serious, 1 patient) Epistaxis (below serious, 1 patient) Hypotension (below serious, 2 patients) |
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Other AEs: Anaemia, Haemorrhagic disorder... Other AEs: Anaemia (serious, 6 patients) Sources: Haemorrhagic disorder (serious, 1 patient) Hilar lymphadenopathy (serious, 1 patient) Lymphadenopathy (serious, 1 patient) Splenic infarction (serious, 1 patient) Angina unstable (serious, 7 patients) Aortic valve incompetence (serious, 1 patient) Arteriospasm coronary (serious, 1 patient) Atrial flutter (serious, 3 patients) Atrioventricular block complete (serious, 2 patients) Cardio-respiratory arrest (serious, 7 patients) Cardiogenic shock (serious, 7 patients) Cardiomyopathy (serious, 1 patient) Cardiopulmonary failure (serious, 2 patients) Coronary artery disease (serious, 4 patients) Left ventricular dysfunction (serious, 1 patient) Low cardiac output syndrome (serious, 1 patient) Fibrosis myocardial (serious, 1 patient) Tachyarrhythmia (serious, 1 patient) Tachycardia (serious, 3 patients) Ventricular extrasystoles (serious, 1 patient) Ventricular tachycardia (serious, 10 patients) Vertigo (serious, 4 patients) Cataract (serious, 3 patients) Retinal detachment (serious, 1 patient) Constipation (serious, 2 patients) Duodenal ulcer haemorrhage (serious, 1 patient) Enterocolitis (serious, 1 patient) Gastritis (serious, 1 patient) Hiatus hernia (serious, 1 patient) Intestinal obstruction (serious, 1 patient) Intestinal polyp (serious, 1 patient) Nausea (serious, 8 patients) Small intestinal obstruction (serious, 1 patient) Umbilical hernia, obstructive (serious, 1 patient) Upper gastrointestinal haemorrhage (serious, 1 patient) Vomiting (serious, 5 patients) Chest discomfort (serious, 1 patient) Chest pain (serious, 6 patients) Device lead issue (serious, 1 patient) Drug intolerance (serious, 1 patient) Necrosis (serious, 1 patient) Non-cardiac chest pain (serious, 7 patients) Soft tissue inflammation (serious, 1 patient) Sudden death (serious, 9 patients) Cholecystitis (serious, 2 patients) Hepatic cirrhosis (serious, 1 patient) Hepatic cyst (serious, 1 patient) Hepatorenal syndrome (serious, 1 patient) Heart transplant rejection (serious, 1 patient) Anal abscess (serious, 1 patient) Appendicitis (serious, 2 patients) Bronchitis bacterial (serious, 1 patient) Erysipelas (serious, 2 patients) Gastrointestinal viral infection (serious, 1 patient) Hepatitis B (serious, 1 patient) Liver abscess (serious, 1 patient) Infection localised (serious, 1 patient) Lower respiratory tract infection (serious, 3 patients) Orchitis (serious, 1 patient) Osteomyelitis acute (serious, 1 patient) Paronychia (serious, 1 patient) Pseudomembranous colitis (serious, 2 patients) Respiratory tract infection (serious, 3 patients) Sepsis (serious, 8 patients) Viral infection (serious, 1 patient) Wound infection pseudomonas (serious, 1 patient) Accidental overdose (serious, 1 patient) Ankle fracture (serious, 1 patient) Contusion (serious, 1 patient) Dermatitis artefacta (serious, 1 patient) Electric shock (serious, 1 patient) Extradural haematoma (serious, 1 patient) Femoral neck fracture (serious, 1 patient) Femur fracture (serious, 4 patients) Head injury (serious, 1 patient) Humerus fracture (serious, 2 patients) Laceration (serious, 1 patient) Post procedural haematoma (serious, 1 patient) Procedural haemorrhage (serious, 1 patient) Pubis fracture (serious, 1 patient) Spinal compression fracture (serious, 1 patient) Splenic rupture (serious, 1 patient) Subdural haematoma (serious, 2 patients) Thermal burn (serious, 1 patient) Toxicity to various agents (serious, 2 patients) Blood creatinine increased (serious, 3 patients) Haemoglobin decreased (serious, 1 patient) International normalised ratio increased (serious, 2 patients) Renal function test abnormal (serious, 1 patient) Decreased appetite (serious, 1 patient) Diabetic ketoacidosis (serious, 1 patient) Failure to thrive (serious, 1 patient) Fluid intake reduced (serious, 1 patient) Hypoglycaemia (serious, 7 patients) Arthralgia (serious, 1 patient) Arthritis (serious, 1 patient) Bursitis (serious, 1 patient) Costochondritis (serious, 1 patient) Joint effusion (serious, 1 patient) Muscular weakness (serious, 1 patient) Pain in extremity (serious, 2 patients) Bladder neoplasm (serious, 1 patient) Colon cancer (serious, 2 patients) Colorectal cancer (serious, 1 patient) Hepatic neoplasm (serious, 1 patient) Hepatobiliary neoplasm (serious, 1 patient) Adenocarcinoma lung (serious, 1 patient) Lung neoplasm malignant (serious, 1 patient) Lung squamous cell carcinoma stage unspecified (serious, 1 patient) Multiple myeloma (serious, 1 patient) Prostate cancer metastatic (serious, 1 patient) Uterine leiomyoma (serious, 1 patient) Anterior spinal artery syndrome (serious, 1 patient) Burning sensation (serious, 1 patient) Cerebral haematoma (serious, 1 patient) Coma (serious, 1 patient) Diabetic neuropathy (serious, 1 patient) Dizziness (serious, 4 patients) Dysarthria (serious, 1 patient) Embolic stroke (serious, 2 patients) Epilepsy (serious, 2 patients) Haemorrhagic stroke (serious, 1 patient) Intracranial haematoma (serious, 1 patient) Loss of consciousness (serious, 1 patient) Metabolic encephalopathy (serious, 1 patient) Myasthenia gravis (serious, 1 patient) Myasthenia gravis crisis (serious, 1 patient) Neuropathy peripheral (serious, 1 patient) Somnolence (serious, 2 patients) Trigeminal neuralgia (serious, 1 patient) Unresponsive to stimuli (serious, 1 patient) Uraemic encephalopathy (serious, 1 patient) Abnormal behaviour (serious, 1 patient) Alcohol abuse (serious, 1 patient) Anxiety (serious, 1 patient) Confusional state (serious, 2 patients) Depression suicidal (serious, 1 patient) Screaming (serious, 1 patient) Bladder tamponade (serious, 1 patient) Haematuria (serious, 1 patient) Nephropathy (serious, 1 patient) Polyuria (serious, 1 patient) Renal artery stenosis (serious, 1 patient) Renal failure acute (serious, 20 patients) Renal impairment (serious, 5 patients) Benign prostatic hyperplasia (serious, 2 patients) Menorrhagia (serious, 1 patient) Acute pulmonary oedema (serious, 7 patients) Acute respiratory distress syndrome (serious, 1 patient) Acute respiratory failure (serious, 2 patients) Asthma (serious, 1 patient) Atelectasis (serious, 1 patient) Bronchiectasis (serious, 1 patient) Chronic obstructive pulmonary disease (serious, 13 patients) Dyspnoea (serious, 20 patients) Pneumonitis (serious, 1 patient) Pneumothorax (serious, 1 patient) Productive cough (serious, 1 patient) Pulmonary artery thrombosis (serious, 1 patient) Respiratory failure (serious, 6 patients) Wheezing (serious, 1 patient) Hyperhidrosis (serious, 2 patients) Skin ulcer (serious, 1 patient) Skin ulcer haemorrhage (serious, 1 patient) Extremity necrosis (serious, 1 patient) Hypotension (serious, 24 patients) Peripheral arterial occlusive disease (serious, 4 patients) Peripheral ischaemia (serious, 1 patient) Disorder peripheral vascular (serious, 2 patients) Phlebitis (serious, 1 patient) Diarrhoea (below serious, 49 patients) Hyperkalaemia (below serious, 155 patients) Renal impairment (below serious, 47 patients) Cough (below serious, 59 patients) Hypotension (below serious, 117 patients) |
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Other AEs: Thrush NOS... Other AEs: Thrush NOS (below serious, 1 patient) Sources: |
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Other AEs: Hyperkalemia... Other AEs: Hyperkalemia (below serious, 1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | 0.6% Disc. AE |
600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 53 |
Angioedema | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Angioedema | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disorder fetal | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hyperkalemia | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hypotension | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Impaired renal function | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Lower extremities weakness of | below serious, 1 patient | 150 mg 1 times / day steady, oral Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: |
unhealthy |
Diarrhea | below serious, 5 patients | 150 mg 1 times / day steady, oral Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: |
unhealthy |
GI bleed | serious, 1 patient | 150 mg 1 times / day steady, oral Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: |
unhealthy |
Knee hemarthrosis | serious, 1 patient | 150 mg 1 times / day steady, oral Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: |
unhealthy |
Arthritis | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Asteroid hyalosis | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Choroidal neovascularisation | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Diarrhoea | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Epistaxis | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Fatigue | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Flatulence | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Foreign body sensation in eyes | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Fungal skin infection | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hypoglycaemia | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Muscle spasms | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Myalgia | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Pain in extremity | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Pain in jaw | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Paraesthesia | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Respiratory tract infection | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Retinal neovascularisation | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Sinusitis | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Tooth fracture | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Vision blurred | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Vitreous detachment | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Basal cell carcinoma | below serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hypotension | below serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Cellulitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Diabetic foot | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Pneumonia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hypotension | below serious, 117 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hyperkalaemia | below serious, 155 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Renal impairment | below serious, 47 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Diarrhoea | below serious, 49 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Cough | below serious, 59 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Abnormal behaviour | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Accidental overdose | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Acute respiratory distress syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Adenocarcinoma lung | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Alcohol abuse | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Anal abscess | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Ankle fracture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Anterior spinal artery syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Anxiety | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Aortic valve incompetence | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Arteriospasm coronary | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Arthralgia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Arthritis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Asthma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Atelectasis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Bladder neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Bladder tamponade | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Bronchiectasis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Bronchitis bacterial | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Burning sensation | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Bursitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Cardiomyopathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Cerebral haematoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Chest discomfort | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Colorectal cancer | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Coma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Contusion | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Costochondritis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Decreased appetite | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Depression suicidal | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Dermatitis artefacta | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Device lead issue | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Diabetic ketoacidosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Diabetic neuropathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Drug intolerance | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Duodenal ulcer haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Dysarthria | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Electric shock | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Enterocolitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Extradural haematoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Extremity necrosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Failure to thrive | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Femoral neck fracture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Fibrosis myocardial | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Fluid intake reduced | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Gastritis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Gastrointestinal viral infection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Haematuria | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Haemoglobin decreased | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Haemorrhagic disorder | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Haemorrhagic stroke | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Head injury | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Heart transplant rejection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hepatic cirrhosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hepatic cyst | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hepatic neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hepatitis B | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hepatobiliary neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hepatorenal syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hiatus hernia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hilar lymphadenopathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Infection localised | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Intestinal obstruction | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Intestinal polyp | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Intracranial haematoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Joint effusion | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Laceration | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Left ventricular dysfunction | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Liver abscess | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Loss of consciousness | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Low cardiac output syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Lung neoplasm malignant | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Lung squamous cell carcinoma stage unspecified | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Lymphadenopathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Menorrhagia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Metabolic encephalopathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Multiple myeloma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Muscular weakness | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Myasthenia gravis crisis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Myasthenia gravis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Necrosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Nephropathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Neuropathy peripheral | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Orchitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Osteomyelitis acute | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Paronychia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Peripheral ischaemia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Phlebitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Pneumonitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Pneumothorax | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Polyuria | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Post procedural haematoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Procedural haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Productive cough | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Prostate cancer metastatic | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Pubis fracture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Pulmonary artery thrombosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Renal artery stenosis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Renal function test abnormal | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Retinal detachment | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Screaming | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Skin ulcer haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Skin ulcer | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Small intestinal obstruction | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Soft tissue inflammation | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Spinal compression fracture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Splenic infarction | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Splenic rupture | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Tachyarrhythmia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Thermal burn | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Trigeminal neuralgia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Umbilical hernia, obstructive | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Unresponsive to stimuli | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Upper gastrointestinal haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Uraemic encephalopathy | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Uterine leiomyoma | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Ventricular extrasystoles | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Viral infection | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Wheezing | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Wound infection pseudomonas | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Ventricular tachycardia | serious, 10 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Chronic obstructive pulmonary disease | serious, 13 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Acute respiratory failure | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Appendicitis | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Atrioventricular block complete | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Benign prostatic hyperplasia | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Cardiopulmonary failure | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Cholecystitis | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Colon cancer | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Confusional state | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Constipation | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Disorder peripheral vascular | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Embolic stroke | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Epilepsy | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Erysipelas | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Humerus fracture | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hyperhidrosis | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
International normalised ratio increased | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Pain in extremity | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Pseudomembranous colitis | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Somnolence | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Subdural haematoma | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Toxicity to various agents | serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Dyspnoea | serious, 20 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Renal failure acute | serious, 20 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hypotension | serious, 24 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Atrial flutter | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Blood creatinine increased | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Cataract | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Lower respiratory tract infection | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Respiratory tract infection | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Tachycardia | serious, 3 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Coronary artery disease | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Dizziness | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Femur fracture | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Peripheral arterial occlusive disease | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Vertigo | serious, 4 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Renal impairment | serious, 5 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Vomiting | serious, 5 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Anaemia | serious, 6 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Chest pain | serious, 6 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Respiratory failure | serious, 6 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Acute pulmonary oedema | serious, 7 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Angina unstable | serious, 7 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Cardio-respiratory arrest | serious, 7 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Cardiogenic shock | serious, 7 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hypoglycaemia | serious, 7 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Non-cardiac chest pain | serious, 7 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Nausea | serious, 8 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Sepsis | serious, 8 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Sudden death | serious, 9 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Thrush NOS | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Hyperkalemia | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 12.0 |
no [Inhibition 100 uM] | |||
Page: 12.0 |
no [Inhibition 100 uM] | |||
Page: 12.0 |
no [Inhibition 100 uM] | |||
Page: 12.0 |
no [Inhibition 100 uM] | |||
Page: 46.0 |
no [Inhibition 200 uM] | |||
Page: 46.0 |
no [Inhibition 200 uM] | |||
Page: 46.0 |
no [Inhibition 200 uM] | |||
Page: 47.0 |
no | |||
Page: 21.0 |
no | |||
Page: 30.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 30, 57 |
inconclusive | |||
Page: 30.0 |
major | yes (co-administration study) Comment: itraconazole increased Cmax by 5-fold and AUC by 6-fold; ketaconazole increased Cmax a nd AUC by 2-fold; cyclosporine increased Cmax by 5-fold and AUC by 3-fold Page: 30.0 |
||
Page: 30, 55, 56 |
minor | |||
Page: 31.0 |
no | |||
Page: 31.0 |
no | |||
Page: 31, 57 |
no | |||
Page: 31, 57 |
no | |||
Page: 31.0 |
yes | yes (co-administration study) Comment: from clinical pharmacology review pdf 4: ketaconazole increased Cmax by 81% and AUC by 76%; from product label: itraconazole increased Cmax by 5-fold and AUC by 6-fold; cyclosporine increased Cmax by 5-fold and AUC by 3-fold Page: 31.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 46, 69 |
PubMed
Title | Date | PubMed |
---|---|---|
Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. | 2006 Dec |
|
Opportunities for structure-based design of protease-directed drugs. | 2006 Dec |
|
[Renin-angiotensin system]. | 2006 Jul |
|
[Antihypertensive drugs in clinical development]. | 2006 May |
|
Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension. | 2006 Oct |
|
New drugs for hypertension: what do they offer? | 2006 Oct |
|
Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. | 2006 Oct |
|
Molecule of the Month. Aliskiren fumarate. | 2006 Sep |
|
Imaging the renin-angiotensin system: an important target of anti-hypertensive therapy. | 2006 Sep 15 |
|
Antihypertensive therapies. | 2007 Aug |
|
[The best of hypertension in 2006]. | 2007 Jan |
|
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. | 2007 Jul 21 |
|
Dual inhibition of the renin system by aliskiren and valsartan. | 2007 Jul 21 |
|
Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. | 2007 Jun |
|
Aliskiren for renin inhibition: a new class of antihypertensives. | 2007 Mar |
|
Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. | 2007 Mar 22 |
|
The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. | 2007 Sep |
|
Inhibition of renin: an updated review of the development of renin inhibitors. | 2007 Sep |
Sample Use Guides
Starting dose: 150 mg once daily with a routine pattern with regard
to meals. If blood pressure remains uncontrolled titrate up to
300 mg daily (2.1, 2.3)
Majority of effect of given dose attained in 2 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27062013
Aliskiren (0.1 or 10 uM) dose-dependently improved functions and increased both VEGF and stromal cell-derived factor-1α (SDF-1α) expression of EPCs from patients with T2DM or EPCs from healthy volunteers and treated with high glucose.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175900
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
WHO-VATC |
QC09XA02
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
WHO-VATC |
QC09XA53
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
WHO-ATC |
C09XA53
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
WHO-ATC |
C09XA54
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
WHO-ATC |
C09XA02
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
WHO-ATC |
C09XA52
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
NDF-RT |
N0000175899
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
WHO-ATC |
C09DX02
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
WHO-VATC |
QC09XA52
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
LIVERTOX |
NBK548884
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
||
|
WHO-VATC |
QC09DX02
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ALISKIREN
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
7843
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
m1509
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
173334-57-1
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
502FWN4Q32
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
DTXSID40891494
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL1639
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
325646
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | RxNorm | ||
|
502FWN4Q32
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
C65222
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
119
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
C446481
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
601027
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
7992
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
RR-38
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
4812
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
100000089565
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
5493444
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
SUB21380
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY | |||
|
DB09026
Created by
admin on Wed Apr 02 08:16:25 GMT 2025 , Edited by admin on Wed Apr 02 08:16:25 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)